SAB Biotherapeutics (SABS) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on June 18, 2026, with voting available online, by phone, or by mail.

• Stockholders will vote on electing four Class II directors for three-year terms and ratifying EisnerAmper LLP as the independent auditor for 2026.

• Only common stockholders as of April 20, 2026, may vote; Series A Preferred Stock reached its voting blocker and will not vote.

• Proxy materials are primarily distributed via Internet to reduce costs and environmental impact.

• Forward-looking statements are included, subject to risks and uncertainties.

Voting matters and shareholder proposals

• Proposals include electing four Class II directors and ratifying EisnerAmper LLP as auditor.

• Board recommends voting FOR all director nominees and FOR auditor ratification.

• No other shareholder proposals were received for this meeting.

• Procedures for submitting proposals and director nominations for the 2027 meeting are detailed, with deadlines and requirements.

Board of directors and corporate governance

• Board consists of 11 directors divided into three classes with staggered terms.

• Majority of directors are independent per Nasdaq rules; all committees are fully independent.

• Board committees include audit, compensation, and nominating/governance, each with defined charters and responsibilities.

• Board leadership is separated between an independent chairman and CEO.

• Directors are selected based on experience, independence, and diversity of skills.